WorldCat Identities

Cotte, Laurent

Overview
Works: 9 works in 9 publications in 1 language and 13 library holdings
Roles: Contributor, Other, Author
Publication Timeline
.
Most widely held works by Laurent Cotte
The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study by Laurent Cotte( )

1 edition published in 2014 in English and held by 2 WorldCat member libraries worldwide

Hepatitis C treatment initiation in HIV-HCV coinfected patients by the Dat'AIDS study Group( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - a case report by Vincent Alcazer( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination by Dat'AIDS Study Group( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Le Cantique des oiseaux! Romance, paroles de Melle Laurent Cotté, musique de Alfred Joly by Alfred Joly( )

1 edition published in 1872 in Undetermined and held by 1 WorldCat member library worldwide

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Abstract : Abstract: Data on the long-term efficacy and safety of abacavir/lamivudine (ABC/3TC) and nevirapine (NVP) are scarce. This combination has the advantage of simplifying treatment and improving long-term tolerance. The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regimen because of virologic failure (VF), and/or adverse drug reaction (ADR) among patients receiving stable ARV regimens for at least 6 months. ABC/3TC/NVP was compared to ABC/3TC with either ritonavir-boosted darunavir (DRV/r) or ritonavir-boosted atazanavir (ATV/r), unboosted ATV, or tenofovir/emtricitabine (TDF/FTC) with either one of the following: ATV/r, unboosted ATV, DRV/r, efavirenz (EFV), or NVP, in the French prospective multicenter Dat'AIDS cohort. The study enrolled 16, 511 patients treated with following ARV regimens: ABC/3TC/NVP (n = 1089), TDF/FTC/NVP (n = 1542), ABC/3TC/DRV/r (n = 1065), ABC/3TC/ATV/r (n = 1847), ABC/3TC/ATV (n = 563), TDF/FTC/ATV/r (n = 3519), TDF/FTC/DRV/r (n = 2767), TDF/FTC/ATV (n = 419), and TDF/FTC/EFV (n = 3700). Mean follow-up was 36 ± 24 months. Patients treated with ABC/3TC/NVP received this regimen as a switch regimen in 97% of cases. By multivariable analysis, the risk of treatment discontinuation due to VF was similar between ABC/3TC/NVP and other ARV regimens, except for TDF/FTC/ATV and ABC/3TC/ATV, which were associated with a higher risk of treatment interruption due to VF (hazard ratio [HR] 1.99; 95% confidence interval [CI] 1.29-3.06 and HR 2.19; 95% CI 1.51-3.18, respectively). Treatment discontinuation due to ADR was lowest with the ABC/3TC/NVP regimen. Other ARV regimens were associated with a 1.80- to 3.19-fold increase in the risk of treatment discontinuation due to ADR (P <0.0001 for all comparisons). ABC/3TC/NVP as a simplification regimen is a long-term effective regimen with lower discontinuation due to long-term toxicity compared with other standard ARV regimens
Costs and benefits of on-demand HIV preexposure prophylaxis in MSM( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract : Objectives: We undertook the economic evaluation of the double-blind randomized ANRS-IPERGAY trial, which showed the efficacy of on-demand preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) in preventing HIV infection among high-risk MSM. Design and methods: The economic evaluation was prospective. Counseling, drugs (TDF-FTC at [Euro sign]500.88 for 30 tablets), tests, visits, and hospital admissions were valued based on in-trial use. The cost of on-demand PrEP/HIV infection averted was compared with the yearly and lifetime costs of HIV infection in France in a cost and benefits analysis. Results: The yearly number of participants needed to treat to prevent one HIV infection was 17.6 (95% confidence interval = 10.7-49.9). The annual cost of counseling was [Euro sign]690/participant. The total 1-year costs of PrEP were [Euro sign]4271/participant, of which [Euro sign]3129 (73%) were drug costs corresponding to 15 tablets of TDF-FTC/month. The yearly cost of on-demand PrEP to avoid one infection was [Euro sign]75 258. Using TDF-FTC generic ([Euro sign]179.9/30 tablets) reduced the 1-year costs of on-demand PrEP to [Euro sign]2271/participant and [Euro sign]39 970/infection averted, respectively. Using TDF-FTC at international market discounted prices ([Euro sign]60/30 tablets) reduced the costs to [Euro sign]1517/participant and the cost to [Euro sign]26 787/infection averted, comparable with the yearly treatment cost of HIV infection in France. On-demand PrEP was found to be cost saving in France if the duration of exposure was less than 7.5 years at current drug price and 13 years at generic price. Conclusion: On-demand PrEP in high-risk MSM with TDF-FTC can be considered cost saving. Other benefits include the treatments of other diseases and reductions in secondary infections
Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract : Abstract: The objective of this study was to estimate the cumulative incidences of failure by months 12 (M12) and 24 (M24) for the most prescribed first-line anti-retroviral regimens (ART). It is retrospective analysis of a prospectively collected database. All patients who initiated their first ART with the most prescribed regimens between 1st January 2004 and 30th June 2013 in 12 large HIV reference centers in France were included. The outcome was treatment failure--defined by any treatment modification for virological or tolerability reasons--and comparisons between regimens were carried out at M12 and M24. Adjusted and weighted methods via the propensity score (PS) were used to compare the effectiveness of the first antiretroviral regimens. Potential confounders of the treatment-outcome association were used to estimate PS with multinomial logistic regression. Overall, 3128 and 2690 patients were included in the M12 and M24 analyses, respectively. Patients received 5 different regimens (ABC/3TC with ATV/r or DRV/r, TDF/FTC with ATV/r, DRV/r, or EFV). Failure was reported in 25% and 42% at M12 and M24, respectively. Patients who received TDF/FTC/EFV had a significantly higher proportion of failure at M12 by comparison with TDF/FTC with DRV/r (reference), but not at M24. Patients in the 3 other groups had a trend toward a higher proportion of failure at M12 although not statistically significant. No difference was found at M24. Using data from a large prospective cohort, we found that boosted atazanavir and darunavir had comparable effectiveness, whatever the associated NRTIs, whereas efavirenz-based regimens were relatively less performing on the short term
La Cloche! Romance, paroles de Melle Laurent Cotté, musique de Alfred Joly by Alfred Joly( )

1 edition published in 1872 in Undetermined and held by 1 WorldCat member library worldwide

 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.95 (from 0.88 for Long-term ... to 0.98 for The effect ...)

WorldCat IdentitiesRelated Identities
Languages